www.public4you.fora.pl

njlpkhgea

URCH 4 years in the future anti-cancer drug sales growth forecast

To 50.3 billion U.S. dollars in size, annual growth rate of 16.5. In 2003 and 2005, global sales of cancer drugs increased by 40, representing the global pharmaceutical sales in 2005 to 8.4. MktI2006, 33 (50) 7 (Tommy Abstract) 06101Forodesine and R & D progress Biocryst peramivir leading pharmaceutical companies products - anti-cancer drugs Forodesine (forodesine) (I) have received treatment in the European Union T cell acute lymphoblastic leukemia Orphan drug status. MundiPharma is (I) the transferee in Europe. Injection (I) is in advanced T cell leukemia patients assessed for Ⅱ a trial for acute lymphoblastic leukemia B cells Phase Ⅱ trials are to proceed in the. (I) in an oral formulation for chronic lymphocytic leukemia Ⅱ trial. (I) is a purine nucleoside phosphorylase (PNP) inhibitor. 2005, (I) received several indications in the United States for the status of rare disease drugs: T-cell non-Hodgkin's lymphoma, including skin T cell lymphoma; chronic lymphocytic leukemia and related leukemia, including T cells prolymphocytic leukemia; adult T cell leukemia and hairy cell leukemia; and B cell acute lymphoblastic leukemia. (I) has been awarded the U.S. treatment of relapsed or refractory T-cell leukemia, the Biocryst in December 2006 that it expected in the upcoming flu season started peramir (Ⅱ) Phase Ⅱ clinical trial. (Ⅱ) is the influenza neuraminidase inhibitor, is being developed for the treatment of seasonal and life-threatening influenza, including avian flu. In preclinical animal model studies have shown that it can enhance the infection of H5N1 virus strains, the survival rate of animals. Scrip2006 (3213) 21 (Jin Weiqiu Abstract) 06102Merck confidence in the company's success with the new strategy has been strengthened by Merck in this year's on the revitalization strategy was growth. Listing of five new products,[link widoczny dla zalogowanych], including HPV vaccine Gandasil (quadrivalent human papillomavirus vaccine). Merck also plans in 2007 to three products with the market, and then apply three products listed, in addition to four in the pilot project for stage Ⅲ. Review in the U.S. FDA for the treatment of diabetes three products Janumet (MK a 0431A), for chemotherapy-induced nausea and vomiting (CINV) of Emend (aprepitant) MK intravenous formulation of a 0517, and follow-up treatment of osteoarthritis COx-2 inhibitors arcoxia (etoricoxib). Areoxia receiving special scrutiny,[link widoczny dla zalogowanych], as it Vioxx (rofecoxib) belongs to the same type, which was withdrawn from the market in 2004. Merck said the company, FDA advisory committee meetings will be open to review of Arcoxia, but has not yet set a date. Some analysts worried that the product is not listed,[link widoczny dla zalogowanych], because it already has several reasons for the delay management of a new declaration, some cardiologists strong opposition allowed. The company's proposed schedule in the latter part of the other in the product under review is a CETP inhibitor MK 0859, is for lipid and HDL / IDL control Ⅱ trial. The compound with Pfizer's torcetrapib is the same type, who had just because the mortality rate in patients taking the placebo group 60 to terminate development of safety data. Merck has long been speculation that CETP inhibitors in development, this is the first time the company acknowledged. Chairman of the company's research laboratories PeterKim said that so far the only information is a two-phase Ⅱ b 8-week trial,[link widoczny dla zalogowanych], did not show increased blood pressure or other safety signals. Phase Ⅲ company said the other products, including a new type of HIV drug MK a 0518, the company developed in collaboration with Lundbeck for the insomnia gaboxadol (gaboxado1), and for the release of atherosclerosis and flushing niacin pathway inhibitors, a mixture of MK 0524A, Merck,[link widoczny dla zalogowanych], all of these products are planned for 2007 listing license. Early trials in stage Ⅲ other compounds for atherosclerosis, including the MK a 0524B, alkali treatment of obesity marijuana class of drugs MK-1 receptor A 0364 for 43 *